US 12,280,060 B2
Methods of treating cancer using neuronal activity inhibiting agents
David Gutmann, St. Louis, MO (US); and Corina Anastasaki, St. Louis, MO (US)
Assigned to Washington University, St. Louis, MO (US)
Filed by David Gutmann, St. Louis, MO (US); and Corina Anastasaki, St. Louis, MO (US)
Filed on Dec. 21, 2022, as Appl. No. 18/069,317.
Claims priority of provisional application 63/331,326, filed on Apr. 15, 2022.
Claims priority of provisional application 63/292,023, filed on Dec. 21, 2021.
Prior Publication US 2023/0190758 A1, Jun. 22, 2023
Int. Cl. A61K 31/53 (2006.01); A61K 31/4192 (2006.01); A61K 38/48 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/53 (2013.01) [A61K 31/4192 (2013.01); A61K 38/4886 (2013.01); A61P 35/00 (2018.01)] 8 Claims
 
1. A method of inhibiting tumor growth in a subject in need thereof, the method comprising:
administering a therapeutically effective amount of a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel agonist comprising at least one of lamotrigine and rufinamide to the subject;
wherein the subject has Neurofibromatosis type 1 (NF1); and
wherein the subject has a nervous system tumor.